What's new for antiretroviral treatment in women with HIV
Currently, women represent 52% of persons infected with HIV worldwide and 23% of those in the United States. Combination antiretroviral therapy (cART) has resulted in remarkable reductions in HIV-associated morbidity and mortality, and has dramatically improved life expectancy. Treatment guidelines...
Main Authors: | Nisha Andany, Sharon L. Walmsley |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-04-01
|
Series: | Journal of Virus Eradication |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664020304726 |
Similar Items
-
Changing the PrEP Narrative: A Call to Action to Increase PrEP Uptake among Women
by: Alina Cernasev, et al.
Published: (2021-06-01) -
Injectable Antiretroviral Drugs: Back to the Future
by: Marco Berruti, et al.
Published: (2021-02-01) -
“PrEP”ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women
by: Elizabeth C. Pasipanodya, et al.
Published: (2021-05-01) -
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion
by: Shui-Shan Lee, et al.
Published: (2020-05-01) -
Integrating Oral PrEP Into Family Planning Services for Women in Sub-saharan Africa: Findings From a Multi-Country Landscape Analysis
by: Neeraja Bhavaraju, et al.
Published: (2021-06-01)